Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipragliflozin + pioglitazone
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**ipragliflozin + pioglitazone** is a combination of two small-molecule oral antidiabetic agents: ipragliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption and promotes urinary glucose excretion; and pioglitazone, a selective agonist of peroxisome proliferator-activated receptor gamma (PPARγ) that improves insulin sensitivity in adipose, muscle, and liver tissues. This combination targets two distinct, complementary mechanisms to improve glycemic control and addresses multiple pathologies in type 2 diabetes, such as insulin resistance and glucose overload. The combination is studied and used for treatment of type 2 diabetes and has been investigated for metabolic dysfunction–associated steatotic liver disease (MASLD, also known as NAFLD/NASH) in patients with type 2 diabetes[1][3][4][5][7].
- Brand names
- no unique fixed-dose combination brand identified
- Other names
- ipragliflozin and pioglitazoneipragliflozin plus pioglitazone
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on ipragliflozin + pioglitazone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipragliflozin + pioglitazone.